NO992804D0 - Benzodioksol, benzofuran, dihydrobenzofuran og benzodioksan melatonergiske midler - Google Patents

Benzodioksol, benzofuran, dihydrobenzofuran og benzodioksan melatonergiske midler

Info

Publication number
NO992804D0
NO992804D0 NO992804A NO992804A NO992804D0 NO 992804 D0 NO992804 D0 NO 992804D0 NO 992804 A NO992804 A NO 992804A NO 992804 A NO992804 A NO 992804A NO 992804 D0 NO992804 D0 NO 992804D0
Authority
NO
Norway
Prior art keywords
benzodioxane
benzodioxole
dihydrobenzofuran
benzofuran
melatonergic agents
Prior art date
Application number
NO992804A
Other languages
English (en)
Other versions
NO321450B1 (no
NO992804L (no
Inventor
John D Catt
Graham Johnson
Daniel J Keavy
Ronald J Mattson
Michael F Parker
Katherine S Takaki
Joseph P Yevich
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO992804D0 publication Critical patent/NO992804D0/no
Publication of NO992804L publication Critical patent/NO992804L/no
Publication of NO321450B1 publication Critical patent/NO321450B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19992804A 1996-12-10 1999-06-09 Benzodioksol-, benzofuran-, dihydrobenzofuran- og benzodioksan-derivater som kan anvendes som melatonergiske midler og anvendelse av disse for fremstilling av farmasoytiske preparater NO321450B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3268996P 1996-12-10 1996-12-10
PCT/US1997/022627 WO1998025606A1 (en) 1996-12-10 1997-12-09 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents

Publications (3)

Publication Number Publication Date
NO992804D0 true NO992804D0 (no) 1999-06-09
NO992804L NO992804L (no) 1999-08-09
NO321450B1 NO321450B1 (no) 2006-05-15

Family

ID=21866306

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992804A NO321450B1 (no) 1996-12-10 1999-06-09 Benzodioksol-, benzofuran-, dihydrobenzofuran- og benzodioksan-derivater som kan anvendes som melatonergiske midler og anvendelse av disse for fremstilling av farmasoytiske preparater

Country Status (26)

Country Link
US (3) US5856529A (no)
EP (1) EP1027043B1 (no)
JP (1) JP4290765B2 (no)
KR (1) KR100499106B1 (no)
CN (1) CN1152679C (no)
AR (1) AR010346A1 (no)
AT (1) ATE281833T1 (no)
AU (1) AU719994B2 (no)
BR (1) BR9713690B1 (no)
CA (1) CA2274183C (no)
CY (1) CY2501B1 (no)
CZ (1) CZ297673B6 (no)
DE (1) DE69731562T2 (no)
DK (1) DK1027043T3 (no)
ES (1) ES2230626T3 (no)
HK (1) HK1029947A1 (no)
HU (1) HU226524B1 (no)
IL (1) IL129999A (no)
NO (1) NO321450B1 (no)
NZ (1) NZ335910A (no)
PL (1) PL190499B1 (no)
PT (1) PT1027043E (no)
RU (1) RU2190609C2 (no)
TW (1) TW476758B (no)
WO (1) WO1998025606A1 (no)
ZA (1) ZA9711051B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614347D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
US6214869B1 (en) 1998-06-05 2001-04-10 Bristol-Myers Squibb Heterocyclic cis cyclopropane derivatives as melatonergic agents
DE60007745T2 (de) 1999-06-30 2005-03-10 Bristol-Myers Squibb Co. Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
ES2264482T3 (es) 2001-05-15 2007-01-01 F. Hoffmann-La Roche Ag Derivados de oxazol sustituidos por acido carboxilico para uso como activadores de ppar-alfa y gamma en el tratamiento de diabetes.
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
JP2005505586A (ja) * 2001-10-04 2005-02-24 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
DE60316290T2 (de) * 2002-07-03 2008-06-12 F. Hoffmann-La Roche Ag Oxazolderivate und deren verwendung als insulinsensibilisatoren
DK1537091T3 (da) * 2002-08-30 2010-11-08 Hoffmann La Roche Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
JP4286782B2 (ja) * 2002-09-12 2009-07-01 エフ．ホフマン−ラ ロシュ アーゲー 糖尿病の治療に有用な、ｐｐａｒアゴニストとしてのｎ−置換−１ｈ−インドール−５−プロピオン酸化合物
DE60323130D1 (de) * 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US7135992B2 (en) * 2002-12-17 2006-11-14 Evolution Robotics, Inc. Systems and methods for using multiple hypotheses in a visual simultaneous localization and mapping system
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2009538334A (ja) 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
RU2488392C2 (ru) * 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
CN101687810A (zh) * 2007-04-26 2010-03-31 武田药品工业株式会社 双环化合物及其药物用途
US7964430B2 (en) * 2007-05-23 2011-06-21 Applied Materials, Inc. Silicon layer on a laser transparent conductive oxide layer suitable for use in solar cell applications
CA2698540A1 (en) * 2007-09-13 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
EP2453891A1 (en) 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP2287159A1 (en) * 2009-07-29 2011-02-23 V.Mane Fils New bicyclic dioxanes, their preparation and their use as organoleptic compounds
PE20131162A1 (es) * 2010-09-22 2013-10-19 Eisai Randd Man Co Ltd Compuestos de ciclopropano como antagonistas del receptor de orexina
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
KR102593047B1 (ko) 2012-01-26 2023-10-24 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR101891299B1 (ko) * 2012-05-18 2018-08-23 반다 파마슈티칼즈, 인코퍼레이티드. (1ｒ-트랜스)-ｎ-[[2-(2,3-디하이드로-4-벤조푸라닐)시클로프로필]메틸]프로판아미드의 대사 산물
US20150368220A1 (en) * 2012-07-10 2015-12-24 Astellas Pharma Inc. Pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, and method for screening compound comprised in said pharmaceutical composition
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
CA2893542C (en) 2012-12-18 2022-07-19 Vanda Pharmaceuticals Inc. Use of tasimelteon in the treatment of circadian rhythm disorders
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
WO2015047113A1 (en) * 2013-09-30 2015-04-02 Polfarmex S.A. Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as η1-receptor antagonists
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP3470405A1 (en) 2014-02-12 2019-04-17 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon
KR20240015729A (ko) 2014-09-02 2024-02-05 반다 파마슈티칼즈, 인코퍼레이티드. 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
CN104327022B (zh) * 2014-10-17 2015-12-02 苏州明锐医药科技有限公司 他司美琼的制备方法
CN104402849B (zh) * 2014-11-11 2016-11-09 苏州莱克施德药业有限公司 他司美琼中间体的新制备工艺
CN106588841B (zh) * 2015-10-19 2019-01-25 富乐马鸿凯（大连）医药有限公司 合成2,3-二氢-1-苯并呋喃-4-甲醛的方法
CN117482062A (zh) 2016-05-06 2024-02-02 雀巢产品有限公司 缬草组合物和相关方法
CN105949153B (zh) * 2016-05-10 2018-03-02 浙江工业大学 一种他司美琼的合成方法
CN107365288A (zh) * 2016-05-12 2017-11-21 浙江京新药业股份有限公司 他司美琼的晶型
US9944616B2 (en) 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
CN106543119B (zh) * 2016-09-22 2019-07-26 浙江工业大学 一种光学纯他司美琼的制备方法
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
WO2018149940A1 (en) 2017-02-17 2018-08-23 Quimica Sintetica, S. A. Process for the preparation of enantiomerically enriched dihydrobenzofurans and intermediate compounds obtained in the process
ES2965488T3 (es) 2017-08-02 2024-04-15 Vanda Pharmaceuticals Inc Uso de tasimelteón para el tratamiento de trastornos afectivos en pacientes mayoritariamente negroafricanos
KR20240007693A (ko) 2018-03-04 2024-01-16 반다 파마슈티칼즈, 인코퍼레이티드. 타시멜테온을 이용한 질환의 치료
CN113365618A (zh) * 2018-09-12 2021-09-07 万带兰制药公司 改善睡眠或睡醒后表现
CN114641284A (zh) 2019-06-29 2022-06-17 万带兰制药公司 他司美琼在治疗睡眠异常中的应用
EP4072542A1 (en) 2019-12-13 2022-10-19 Vanda Pharmaceuticals Inc. Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2667316B1 (fr) * 1990-10-02 1994-09-16 Roussel Uclaf Nouveaux derives du benzofuranne, leur procede de preparation et leur application comme pesticides.
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
CA2176854A1 (en) * 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
JP2000511518A (ja) * 1996-05-14 2000-09-05 グラクソ、グループ、リミテッド 時間生物学的薬剤としてのベンゾフランおよびベンゾピラン

Also Published As

Publication number Publication date
ZA9711051B (en) 1999-06-09
ES2230626T3 (es) 2005-05-01
PL190499B1 (pl) 2005-12-30
JP4290765B2 (ja) 2009-07-08
US6060506A (en) 2000-05-09
HUP0000695A2 (hu) 2001-05-28
CN1152679C (zh) 2004-06-09
EP1027043B1 (en) 2004-11-10
CZ199199A3 (cs) 1999-09-15
KR100499106B1 (ko) 2005-07-01
CA2274183C (en) 2006-10-24
HUP0000695A3 (en) 2002-09-30
ATE281833T1 (de) 2004-11-15
US5981571A (en) 1999-11-09
KR20000069396A (ko) 2000-11-25
AU719994B2 (en) 2000-05-18
CY2501B1 (en) 2005-09-02
BR9713690A (pt) 2000-05-02
CZ297673B6 (cs) 2007-02-28
RU2190609C2 (ru) 2002-10-10
NZ335910A (en) 2000-11-24
WO1998025606A1 (en) 1998-06-18
IL129999A (en) 2004-06-20
US5856529A (en) 1999-01-05
PL333950A1 (en) 2000-01-31
AR010346A1 (es) 2000-06-07
EP1027043A4 (en) 2002-02-20
CA2274183A1 (en) 1998-06-18
CN1239886A (zh) 1999-12-29
DE69731562D1 (de) 2004-12-16
TW476758B (en) 2002-02-21
AU5598598A (en) 1998-07-03
NO321450B1 (no) 2006-05-15
JP2001505916A (ja) 2001-05-08
HK1029947A1 (en) 2001-04-20
DK1027043T3 (da) 2005-01-10
DE69731562T2 (de) 2005-11-24
IL129999A0 (en) 2000-02-29
NO992804L (no) 1999-08-09
PT1027043E (pt) 2005-02-28
EP1027043A1 (en) 2000-08-16
BR9713690B1 (pt) 2009-08-11
HU226524B1 (en) 2009-03-30

Similar Documents

Publication Publication Date Title
NO992804D0 (no) Benzodioksol, benzofuran, dihydrobenzofuran og benzodioksan melatonergiske midler
ATE334125T1 (de) (benzodioxan, benzofuran, oder benzopyran) derivate mit fundic entspannungseigenschaften
PT1173431E (pt) Metodo de preparacao do citalopram
DK0901483T3 (da) Benzofuraner og benzopyraner som kronobiologiske midler
DE59708166D1 (de) Röntgenaufnahme-Verfahren
KR950700288A (ko) 5-에이취티4 길항제로서의 벤조피란, 벤조티오피란 및 벤조푸란 유도체(Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists)
NO20011460D0 (no) Cytokinreseptor zalphall
ATE203528T1 (de) Antineurodegenerativ wirksame 10-aminoaliphatyl- dibenz- b,f oxepine
FI962419A0 (fi) Ringoskillator med hoeg hastighet
DE69723593D1 (de) Wahrnehmbarer Gehörschutzstöpsel
DE50007501D1 (de) Benzofuranderivate
IS2247B (is) Bensófúran afleiður, framleiðsla þeirra og notkun
DE69630678D1 (de) Spaltenmultiplexer
NL1004459A1 (nl) Geluidwerende elementen.
DE29601515U1 (de) Doppelkrone
ID17503A (id) Metoda konstruksi
FI980993A0 (fi) Betoni/teräs-liittorakenteinen leukapalkki
FR2743503B1 (fr) Jeu de construction
KR970062540U (ko) 방음 블록
SE9600813D0 (sv) Dynamisk hantel
FI963442A0 (fi) Laparakenne salibandy- tai vastaava mailaa varten
KR980003227U (ko) 공사장용 안전 그물망
KR980000257U (ko) 건강 모자
FIU960047U0 (fi) Sarjalomake
KR970002823U (ko) 락 뱅크

Legal Events

Date Code Title Description
MK1K Patent expired